MIP-3 beta/CCL19 蛋白, Mouse

MIP-3 beta/CCL19 Protein, Mouse is a CC chemokine that is strongly chemotactic for CD4 T cells and CD8 T cells and acts as a ligand that binds specifically to the chemokine receptor CCR7 to mediate tissue immunity, inflammatory responses, and antiviral infections. MIP-3 beta/CCL19 Protein, Mouse is a recombinant mouse MIP-3 beta/CCL19 (G26-S108) protein expressed by E. coli^[1][2].

CCL19，也称为 MIP-3 beta，是一种免疫稳定趋化因子，位于人类基因组的第 9 号染色体上。CCL19在胸腺和淋巴结中大量表达，在气管和结肠中中等表达，在胃、小肠、肺、肾和脾中表达较少。CCL19 与趋化因子受体 CCR7 结合并发挥其作用。CCR7 是第一个 CCR7 是第一个被鉴定具有七个跨膜 α 螺旋的淋巴细胞特异性 G 蛋白偶联受体 (GPCR)。CCR7 在双阴性和单阳性胸腺细胞上表达，包括幼稚 T 细胞、中央记忆 T 细胞、调节性 T 细胞、幼稚 B 细胞、半成熟/成熟 DC 和 NK 细胞，以及一些肿瘤细胞，其中作为将稳态淋巴细胞引导至次级淋巴器官的关键调节器。相比之下，CCL19 是唯一已知能有效刺激 β-arrestin 介导的 CCR7 磷酸化和内化的趋化因子，导致受体脱敏和抗原 (Ag) 呈递 DC 迁移，从而影响 T 细胞反应。基于CCL19-CCR7的信号通路在组织免疫和炎症反应记忆中发挥重要作用。此外，它还在针对多种病毒的疫苗保护中发挥作用，例如HIV-1感染、丙型肝炎病毒（HCV）和单纯疱疹病毒1（HSV-1）等。CCL19的相互作用而且 CCR7 还有助于免疫细胞释放抗病毒相关细胞因子（例如 IFN-γ 和 IL-4），从而促进 T 细胞增殖和 DC 摄取抗原^{[1] [2]}.

CCL19 (1 μg/mL, 6 h) induces T cell proliferation in immature mouse dendritic cells (DC)-T cell co-culture systems, induces upregulation of costimulatory molecules and cytokine production in DCs, and maturation of DC to induce the Th1 response in DC isolated from spleens and mesenteric lymph nodes of naïve BALB/c mice^[3].

CCL19 (5 mg/mouse by osmotic pump) significantly increases IL-10 production in plt (plt) mice，and after treatment with 100 mg acetylcholine, the number of lymphocytes at bronchoalveolar lavage fluid (BALF) and enhanced pause (Penh) levels is significantly lower in CCL19-treated mice than in untreated mice^[2].
CCL19 can lead to rapid clearance of intrahepatic HBV likely through increased intrahepatic CD8+ T-cell proportion, decreased frequency of PD-1⁺ CD⁸⁺ T cells in blood and compromised suppression of hepatic APCs, with lymphocytes producing a significantly high level of Ag-responsive TNF-α and IFN-γ from CD⁸⁺ T cells in C57BL/6 mice transfected with the mouse CCL19-encoding plasmid^[4].

1.Full biological activity determined by a chemotaxis bioassay using human mature dendritic cells is in a concentration range of 10-100 ng/ml.
2.Biological activity was determined by its ability to chemoattract Jurkat human T cells using a concentration of 28.96-38.19 ng/mL.

Mouse

E. coli

Tag Free

O70460 (G26-S108)

24047  [NCBI]

GANDAEDCCLSVTQRPIPGNIVKAFRYLLNEDGCRVPAVVFTTLRGYQLCAPPDQPWVDRIIRRLKKSSAKNKGNSTRRSPVS

Approximately 9.2-12 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4 or 0.1% TFA, pH 2.5.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Yan Yan, et al. CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. Front Cell Dev Biol. 2019 Oct 1;7:212.  [Content Brief]

  [2]. Zhang X, et al. Increased CCL19 expression is associated with progression in cervical cancer. Oncotarget. 2017 May 18;8(43):73817-73825.  [Content Brief]

  [3]. Naomi Yamashita, et al. Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model. J Allergy Clin Immunol. 2006 May;117(5):1040-6  [Content Brief]

  [4]. Benjamin J Marsland, et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity. 2005 Apr;22(4):493-505.  [Content Brief]

  [5]. Yan Yan, et al. CCL19 enhances CD8+ T-cell responses and accelerates HBV clearance. J Gastroenterol. 2021 Aug;56(8):769-785.  [Content Brief]